News

A single-center study assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

A substantial benefit noted for EtranaDez and val-rox is that they are delivered as a single-dose.

Nanoscope Therapeutics’ Phase 2 STARLIGHT open-label trial enrolled 6 subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In nonclinical studies, AK-OTOF was well-tolerated in both mice and non-human primates.

The gene therapy received a conditional marketing approval in the European Union in August 2022.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.

A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.

Review top news and interview highlights from the week ending September 9, 2022.

BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.

The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.

iECURE is planning to submit an IND for GTP-506 in mid-2023.

Postmortem analyses revealed cell survival and GDNF production in transplanted areas.

Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.

Precision Bio is taking a novel approach to gene editing to deploy a cure for patients with chronic hepatitis B.

The chief medical officer of Passage Bio discussed research needs in FTD.

Review top news and interview highlights from the week ending September 2, 2022.

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

The company has filed a patent for the new approach, which is designed to combat T-cell exhaustion.

The risk-benefit assessment determined that there are no significant safety concerns.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.